Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  JIM - Journal of Immunological Methods

• Publication date

  2007-01-30

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.JIM.2006.10.013PMID 17196217
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study.

  2006cited by this paper
• Derepression of the Her-2 uORF is mediated by a novel post-transcriptional control mechanism in cancer cells.

  2006cited by this paper
• Tumor imaging using a picomolar affinity HER2 binding affibody molecule.

  2006cited by this paper
• Directed evolution of ATP binding proteins from a zinc finger domain by using mRNA display.

  2006cited by this paper
• Engineering novel binding proteins from nonimmunoglobulin domains

  2005cited by this paper
• Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma

  2005cited by this paper
• Chemical Synthesis of Triple‐Labelled Three‐Helix Bundle Binding Proteins for Specific Fluorescent Detection of Unlabelled Protein

  2005cited by this paper
• Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines.

  2005cited by this paper
• Affibody protein capture microarrays: synthesis and evaluation of random and directed immobilization of affibody molecules.

  2005cited by this paper
• Selection and characterization of HER2/neu-binding affibody ligands.

  2004cited by this paper
• Site-specific and reversible anchoring of active proteins onto cellulose using a cellulosome-like complex.

  2004cited by this paper
• Binding proteins from alternative scaffolds.

  2004cited by this paper
• Fluorescence resonance energy transfer-based detection of analytes using antiidiotypic affinity protein pairs.

  2004cited by this paper
• Inclusion of a non-immunoglobulin binding protein in two-site ELISA for quantification of human serum proteins without interference by heterophilic serum antibodies.

  2003cited by this paper
• Affibody-beta-galactosidase immunoconjugates produced as soluble fusion proteins in the Escherichia coli cytosol.

  2003cited by this paper
• Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.

  2003cited by this paper
• Inhibition of the CD28-CD80 co-stimulation signal by a CD28-binding affibody ligand developed by combinatorial protein engineering.

  2003cited by this paper
• A novel affinity gene fusion system allowing protein A-based recovery of non-immunoglobulin gene products.

  2002cited by this paper
• Construction and characterization of affibody-Fc chimeras produced in Escherichia coli.

  2002cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A.

  2001cited by this paper
• Basic science of HER-2/neu: a review.

  1999cited by this paper
• An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein.

  1999cited by this paper
• The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

  1998cited by this paper
• The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy.

  1998cited by this paper
• Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain

  1997cited by this paper
• HER‐2/neu Signal Transduction in Human Breast and Ovarian Cancer

  1997cited by this paper
• Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.

  1996cited by this paper
• A combinatorial library of an alpha-helical bacterial receptor domain.

  1995cited by this paper
• A combinatorial library of an α-helical bacterial receptor domain

  1995cited by this paper
• Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry.

  1994cited by this paper
• A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells

  1993cited by this paper
• p185neu expression in human lung adenocarcinomas predicts shortened survival.

  1990cited by this paper
• HER-2/neu amplification predicts poor survival in node-positive breast cancer.

  1990cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper

• Design of 3D spheroid models for drug-response studies of HER2-targeted radiopharmaceuticals.

  2025cites this paper
• Amphiphilic Affibody-PROTAC conjugate Self-Assembled nanoagents for targeted cancer therapy

  2024cites this paper
• Robust visualization of membrane protein by aptamer mediated proximity ligation assay and Förster resonance energy transfer.

  2024cites this paper
• A Simple and Low-cost Preliminary Quantification of Target Membrane Protein in Single Cells

  2023cites this paper
• Introduction to Antibody Engineering

  2021influential citation
• Photo-controlled reversible binding between the protein A-derived Z domain and immunoglobulin G.

  2020cites this paper
• Alternative Binding Scaffolds: Multipurpose Binders for Applications in Basic Research and Therapy

  2020cites this paper
• 3D Imaging Detection of HER2 Based in the Use of Novel Affibody-Quantum Dots Probes and Ratiometric Analysis

  2018cites this paper
• Affibody‐derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over‐expressing tumors

  2018cites this paper
• A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer

  2018cites this paper
• Production of a novel Affimer based biosensor for the detection of porcine reproductive and respiratory syndrome virus nucleocapsid protein.

  2017cites this paper
• Chemically-defined camelid antibody bioconjugate for the magnetic resonance imaging of Alzheimer's disease

  2017cites this paper
• Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin.

  2016cites this paper
• Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors

  2016cites this paper
• Recent developments in recognition elements for chemical sensors and biosensors

  2015cites this paper
• Bacteria-based methods for engineering and characterization of proteases and affinity proteins

  2015cites this paper
• Cancer Stratification by Molecular Imaging

  2015cites this paper
• Analytical applications of affibodies

  2015cites this paper
• Engineered Affibodies in Translational Medicine

  2014cites this paper
• DONG LIN NEW GENERATION AFFIBODY MOLECULE PHAGE LIBRARY FOR HIGHLY STRINGENT BINDER SELECTIONS

  2014cites this paper
• Engineering of Affibody molecules for Radionuclide Molecular Imaging and Intracellular Targeting

  2013cites this paper
• [99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours

  2013cites this paper
• Affibodies as an alternative to antibodies inbiosensors for cancer markers

  2012cites this paper
• Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule

  2012cites this paper
• Affibody-DyLight Conjugates for In Vivo Assessment of HER2 Expression by Near-Infrared Optical Imaging

  2012cites this paper
• Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule 111In-DOTA-ZIGF1R:4551

  2012cites this paper
• In Vivo Method to Monitor Changes in HER2 Expression Using Near-Infrared Fluorescence Imaging

  2012cites this paper
• An Engineered Affinity Protein-affibody: An Engineered Affinity Protein-affibody

  2012cites this paper
• Single Molecule Fluorescence Detection and Tracking in Mammalian Cells: The State-of-the-Art and Future Perspectives

  2012cites this paper
• Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels

  2011cites this paper
• Protein-based tumor molecular imaging probes

  2011cites this paper
• HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors

  2011cites this paper
• Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate.

  2011cites this paper
• Design and Evaluation of Radiolabeled Affibody Tracers for Imaging of HER2-expressing Tumors

  2011cites this paper
• Overexpression of OGFr Downregulates Ovarian Cancer Cell Proliferation in Vitro and Inhibits Tumorigenesis

  2011cites this paper
• Tuning calcium binding affinities and related biological fuctions of calmodulin and designing protein based contrast agent

  2011cites this paper
• Ribosome display for selection and evolution of affibody molecules

  2011cites this paper
• Selection of affibody molecules to the ligand‐binding site of the insulin‐like growth factor‐1 receptor

  2010cites this paper
• Design of an optimized scaffold for affibody molecules.

  2010cites this paper
• Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications

  2010influential citation
• HER2‐ and EGFR‐Specific Affiprobes: Novel Recombinant Optical Probes for Cell Imaging

  2010cites this paper
• Engineered affinity proteins--generation and applications.

  2009cites this paper
• The influence of Bz-DOTA and CHX-A″-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy

  2009influential citation
• Evaluation of the Radiocobalt-Labeled [MMA-DOTA-Cys61]-ZHER2:2395-Cys Affibody Molecule for Targeting of HER2-Expressing Tumors

  2009cites this paper
• Selection and characterization of Affibody® ligands to the transcription factor c‐Jun

  2009cites this paper
• RESEARCH ARTICLE SPECT Imaging with 99m Tc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression

  2008cites this paper
• SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression

  2008cites this paper
• Alternative binding proteins: Affibody binding proteins developed from a small three‐helix bundle scaffold

  2008cites this paper
• Imaging of HER-2 overexpression in tumors for guiding therapy.

  2008cites this paper
• Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule.

  2008cites this paper
• Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules.

  2008cites this paper
• Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging

  2008cites this paper
• Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.

  2008cites this paper
• Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy.

  2007cites this paper
• Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.

  2007cites this paper